BMY · Analyze

Date: 2026-07-14 | Price: $58.09 | Sector: Healthcare (large-cap pharma) | Verdict conviction: [6.0] — BUY (income + optionality; size moderate)

---

Snapshot

Metric	Value
Price	$58.09
FY2026 adj EPS guide	$6.05–$6.35 → fwd P/E ~9.4x
P/FCF	~9.3x
EV/EBITDA	~9.3x
Div yield	~4.2%
Gross / op margin	71% / 28.5%
ROE (2025)	43.6% (2024 was −40% on Karuna IPR&D writeoff)

1. Fundamentals — 🔵 cheap cash machine, one big overhang

• FY2026 guide: rev $46.0–47.5B, adj EPS $6.05–6.35. At $58.09 that's ~9.4x forward earnings, ~9.3x P/FCF, 4.2% dividend yield — genuinely cheap for a 71%-gross-margin franchise.
• 2024's negative ROE was a one-time acquired-IPR&D charge (Karuna/Cobenfy deal); 2025 normalized to 43.6% ROE, 14.6% net margin.
• Strong FCF funds the dividend (a 4.2% yield with a manageable FCF payout) and continued deleveraging.

2. Moat & the Overhang — 🟡 real IP moat, real patent cliff

Moat: patents/brands/IP + a hard-to-replicate oncology & immunology franchise. But the moat is time-limited by design — patents expire.

The overhang (the whole story): Eliquis + Opdivo ≈ half of earnings, both lose US exclusivity ~2028. Analysts peg BMS's patent-cliff gap at ~$38B at-risk revenue — the largest among large-cap pharma. This is why it's cheap. The question is purely value-vs-value-trap: can the growth portfolio replace the cliff?

The offset (working, so far): the growth portfolio — Cobenfy (KarXT, novel schizophrenia drug), Reblozyl, Camzyos, Opdualag, Breyanzi — grew +12% in Q1, offsetting a −6% legacy decline for +3% companywide. 2026 has 6 pivotal readouts, the key call options being Cobenfy in Alzheimer's-disease psychosis (Phase 3, end-2026) and Milvexian (oral Factor XIa, stroke prevention, Phase 3). A Cobenfy label expansion into Alzheimer's psychosis would be a multi-billion-dollar swing factor.

3. Valuation

Model	Output
Fwd P/E	~9.4x on $6.20 adj EPS
P/FCF	~9.3x
DYT	4.2% yield vs its own ~3–4% history = at the cheap end
Fair value	10–11x $6.20 → $62–68, with downside support ~$50–52 from FCF/yield

Fair value $58–68 (base ~$63); the 4.2% yield + 9x FCF cap the downside near ~$50. Current $58.09 = fair-to-slightly-cheap with the pipeline as free-ish optionality.

Verdict — BUY, moderate size [6.0]

This is an income-with-optionality play, not a compounder. You're paid 4.2% and buying at ~9x forward to wait on whether the growth portfolio (led by Cobenfy) can fill a $38B hole by 2028. It's cheap because the cliff is real — a textbook value-vs-value-trap, currently trending toward "value" (growth portfolio +12%, offsetting the decline) but unresolved.

• Entry: fair at $58; add on weakness to $50–53 (where yield/FCF support kicks in). Trim $70+.
• Size: suitable for the income sleeve of Beta at a moderate weight — the yield and cheapness are real, but the 2028 cliff caps how large this should be. Don't treat it as a core compounder.
• Risks: (1) 2028 Eliquis/Opdivo cliff bigger than the portfolio can offset → value trap; (2) a key pivotal readout (Cobenfy Alzheimer's, Milvexian) fails; (3) US drug-pricing policy (IRA negotiation) pressure.
• Thesis break: growth portfolio decelerates below legacy-decline offset (companywide growth turns negative for 2+ quarters), or a major 2026 pivotal readout fails.

Sources: roic.ai; BMS 2026 guide & patent cliff, pipeline/Cobenfy. Public.com quote.